Home   Site Map   About Roche   Contact Us   Help   
This is a alt text for HepatologyThis is a alt text for Hepatology
Clinical. Credible. Convenient.
Main Menu
Hepatology Home
News
Clinical Trials
Education
Publications
Resources
Meeting Calendar

Select a link below to view details.
Previous July 2008 Next
S M T W T F S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    
Tell us what you think »
Hepatology Publications

Display by:    Publication date     Author     Alphabetical by Publication Title  
  Hornberger J
infotrieve.gif Locked Content Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
Journal of Clinical Virology 2006 36(): 283 - 291
 
  Howell C
infotrieve.gif Locked Content Peginterferon alfa-2a and Ribavirin for Chronic Hepatitis C Genotype 1 Infections in Black Patients: Safety, Tolerability and Impact on Sustained Virologic Response
Journal of viral hepatitis 2006 13(): 371 - 376
 
  Conjeevaram HS
infotrieve.gif Locked Content Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients with Chronic Hepatitis C Genotype 1
Gastroenterology 2006 131(): 470 - 477
 
  Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.
infotrieve.gif Locked Content Peginterferon-alpha2a, lamivudine and the combination for HBeAG-positive chronic hepatitis B
N Engl J Med 2005 352(26): 2682 - 2695
 
  Rodriguez-Torres M
infotrieve.gif Locked Content Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.
Antimicrobial agents and chemotherapy 2005 49(): 3997 - 4008
 
  Inati A
infotrieve.gif Locked Content Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection.
British journal of haematology 2005 130(): 644 - 646
 
  Juarez-Navarro A, Vera-de-Leon L, Navarro JM
infotrieve.gif Locked Content Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-α2a plus ribavirin in chronic hepatitis C infection
Methods Find Exp Clin Pharmacol. 2005 27(5): 317 - 322
 
  Khalili M, Bernstein D, Lentz E
infotrieve.gif Locked Content Pegylated interferon α-2a with or without ribavirin in HCV/HIV coinfection: Partially blinded, randomized multicenter trial.
Dig Dis Sci. 2005 50(6): 1148 - 1155
 
  Hassanien TI, Cooksley W, Sulkowski M
infotrieve.gif Locked Content The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C
Journal of Hepatology. 2004 40(): 675 - 681
 
  Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, Solsky J, Torriani FJ, Dieterich D, Larrey D
infotrieve.gif Locked Content Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy
AIDS. 2004 18(13): F21 - 25